Creative Planning’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2016
Q4
Sell
-413,500
Closed -$224K 5133
2016
Q3
$224K Buy
413,500
+209,100
+102% +$95.6K ﹤0.01% 1341
2016
Q2
$119K Buy
204,400
+52,400
+34% +$55.9K ﹤0.01% 1562
2016
Q1
$222K Buy
152,000
+11,000
+8% +$21.7K ﹤0.01% 1161
2015
Q4
$451K Buy
141,000
+9,400
+7% +$45.2K ﹤0.01% 814
2015
Q3
$823K Buy
131,600
+4,600
+4% +$43K 0.01% 539
2015
Q2
$1.26M Buy
127,000
+2,000
+2% +$17.5K 0.01% 408
2015
Q1
$921K Buy
125,000
+3,500
+3% +$23.6K 0.01% 496
2014
Q4
$650K Buy
121,500
+19,500
+19% +$99.8K 0.01% 596
2014
Q3
$513K Buy
+102,000
New +$627K 0.01% 649

Other funds holding NWBO

Creative Planning's NWBO Position: Q4 2016 in Review

Creative Planning sold out of Northwest Biotherapeutics, Inc. Common stock (NWBO) in Q4 2016, closing a stake of 413,500 shares — an estimated $224K sold.

Creative Planning first reported a position in NWBO in Q3 2014 and held it in 9 quarters. The position peaked at $1.26M in Q2 2015. 8 funds tracked by Wall St. Rank hold NWBO as of Q4 2016.

  • Creative Planning reported no remaining Northwest Biotherapeutics, Inc. Common stock position as of Q4 2016 after selling out during the quarter.
  • Creative Planning sold 413,500 Northwest Biotherapeutics, Inc. Common stock shares in Q4 2016, an estimated $224K.
  • Creative Planning first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q3 2014 and held it in 9 quarters.
  • Creative Planning's Northwest Biotherapeutics, Inc. Common stock position peaked at $1.26M in Q2 2015.
  • 8 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q4 2016.

Based on Creative Planning's 13F filing for Q4 2016, filed 9 Jan 2017.